Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oraltreatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin.